ADAMTS13 in Thrombotic Thrombocytopenic Purpura
NCT00426686 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153
Last updated 2012-12-12
Summary
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy defined by the spontaneous formation of platelet thrombi in the microvessels. These platelet microthrombi are responsible for a mechanical hemolytic anemia, a thrombocytopenia and a multivisceral ischemia. TTP is a rare but life-threatening disease in the absence of appropriate treatment (PLASMATHERAPY). The onset of the disease usually occurs in adulthood (MOSCHCOVITZ syndrome) and rarely in childhood (UPSHAW-SCHULMAN syndrome). TTP is either sporadic or recurrent with multiple unpredictable relapses. TTP pathophysiology has remained obscure until a new metalloprotease, ADAMTS13, has been demonstrated to be involved in about 90% of all cases. Physiologically, ADAMTS13 function consists in limiting the size of von Willebrand factor (VWF) multimers and consequently, their hemostatic capacity. A large majority of TTP is associated with a severe deficiency of ADAMTS13. In most cases, ADAMTS13 severe deficiency is acquired via auto-antibodies to ADAMTS13; more rarely, ADAMTS13 deficiency is hereditary via ADAMTS13 gene mutations. ADAMTS13 auto-antibodies are either inhibitory of the catalytic activity or non inhibitory. ADAMTS13 mutations are spread all over the gene.
TTP prognosis is quite heterogeneous. Indeed, in about one third of the patients, TTP is refractory to PLASMATHERAPY and/or chronic relapsing. Until now, TTP prognosis factors are not known. Their identification is however crucial both to adapt the curative treatment of an acute episode (addition of first intention immunosuppressive agents to PLASMATHERAPY) and to prevent relapses.
In this context, the aim of the current project is to identify some ADAMTS13 related prognosis factors in TTP. A national prospective multicenter study including both adult and pediatric patients with TTP related to a severe ADAMTS13 deficiency will be designed over a three-year period. This study will involve our group as the French reference center for ADAMTS13 and 10 clinical departments from various French hospitals. Patients will be tested for ADAMTS13 activity and antigen, ADAMTS13 antibodies and ADAMTS13 gene sequencing. Our main hypothesis is that the inactivation of the ADAMTS13 domains crucial for its catalytic activity, either by inhibitory auto-antibodies (acquired TTP) or by genetic mutations (hereditary TTP) is a major bad prognosis factor.
Conditions
- Thrombotic Thrombocytopenic Purpura
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
paul COPPO, MD, PhD · Hôpital Saint Antoire, PARIS
-
Elie AZOULAY, MD, PhD · Hôpital Saint Louis Paris
-
Benoît SCHLEMMER, MD · Hôpital Saint Louis Paris
-
Eric OKSENHENDLER, MD · Hôpital Saint Louis Paris
-
Fadi FAKHOURI, MD · Hôpital Necker, PARIS
-
Jean-Paul MIRA, MD, PhD · Hôpital Cochin, PARIS
-
Eric RONDEAU, MD · Hôpital Tenon, PARIS
-
Jean-paul VERNANT, MD · Hôpital la Pitié Salpétrière, PARIS
-
Nicolas SCHLEINITZ, MD · CHU Conception, MARSEILLE
-
Gilles KAPLANSKI, MD, PhD · CHU Conception, MARSEILLE
-
Albert BENSMAN, MD · Hôpital Trousseau, PARIS
-
Chantal LOIRAT, MD · Hôpital Robert Debré, PARIS
-
Brigitte BADER-MEUNIER, MD · Hôpital Robert Debré, PARIS
-
Christophe PIGUET, MD · Hôpital Dupuytren, LIMOGES
-
Guy PUTET, MD · Hospices civils de LYON, LYON
-
Béatrice DUCOT, MD · INSERM U569 Kremlin Bicêtre, Paris
-
Agnes VEYRADIER, MD, PhD · Hôpital Antoine Béclère, CLAMART
-
Thierry LEBLANC, MD · Hôpital Saint Louis Paris
-
Patrick NIAUDET, MD, PhD · Hôpital Necker, PARIS
-
Christophe RIDEL, MD · Hôpital Tenon, PARIS
-
Pascale POULLIN, MD · CHU de la Conception, MARSEILLE
-
arlos FRANGIE, MD · Hôpital Bicêtre, LE KREMLIN BICETRE
-
Hélène FRANCOIS, MD · Hôpital Bicêtre, LE KREMLIN BICETRE
-
Olivier LAMBOTTE, MD · Hôpital Bicêtre, LE KREMLIN BICETRE
-
Dominique BORDESSOULE, MD, PhD · Hôpital Dupytren, LIMOGES
-
Stéphane GIRAULT, MD · Hôpital Dupytren, LIMOGES
-
Hervé CHAMBOST, MD · Hôpital de la Timone Enfants, Marseilles
-
Pierre BORDOGONI, MD, PhD · Hôpital de Brabois-Hôpital d'Enfants, Vandoeuvre-lès-Nancy
-
Alexandra SALMON, MD · Hôpital de Brabois- hôpital d'enfants, Vandoeuvre-lès-Nancy
-
Laurence CLEMENT, MD · Hôpital de Brabois-Hôpital d'enfants, Vandoeuvre-lès-Nancy
-
Christian COMBE, MD, PhD · Hôpital Pellegrin, Bordeaux
-
Sandrine MEUNIER, MD · Hôpital Edouard Heriot, Lyon
-
Gwenaêlle ROUSSEY, MD · Hôpital Hotel Dieu, Nantes
-
Mohammed HAMIDOU, MD, PhD · Hôpital Hotel Dieu, Nantes
-
Bernard BONNOTTE, MD, PhD · Hôpital du Bocage, Dijon
-
Yves TANTER, MD · Hôpital du Bocage, Dijon
-
Jacques POURRAT, MD, PhD · Hôpital de Rangueil, Toulouse
-
Marie-Christine THOURET, MD · CHU de l'Archet 2, Nice
-
Philippe VANHILLE, MD · CH de Valenciennes, Valenciennes
-
Nicolas LIMAL, MD · Hôpital Henri Mondor, Créteil
-
Philippe REMY, MD · Hôpital Henri Mondor, Créteil
-
Jean-Michel KORACH, MD · CHG Châlons-en-Champagne, Châlons-en-Champagne
-
Carine GREIB, MD · Hôpital Haut-Lévêque, Pesac
-
Jean-Louis PALLOT, MD · CHI André Grégoire, Montreuil
-
Alain WYNCKEL, MD · CHU de Reims, Reims
-
Claire CAZALETS, MD · Hôpital Sud, Rennes
-
Bertrand DE CAGNY, MD · CHU d'Amiens, Amiens
-
Claire PRESNE, MD · CHU D'Amiens, Amiens
-
Cécile FOHRER, MD · Hôpital de Haute-Pierre, Strasbourg
-
Karin BILGER, MD · Hôpital de Haute-Pierre, Strasbourg
-
Bruno LIOURE, MD · Hôpital de Haute-Pierre, Strasbourg
-
Raoul HERBRECHT, MD, PhD · Hôpital de Haute-Pierre, Strasbourg
-
Dominique PLANTAZ, MD, PhD · Hôpital Nord, Grenoble
-
Hubert NIVET, MD, PhD · Hôpital Gatien de Clovheville, Tours
-
Emmanuel FLECK, MD · Hôpital Saint Louis, La Rochelle
-
Jean-Philippe COINDRE, PH · Centre Hospitalier du Mans, LE MANS
-
François MAURIER, PH · Hôpital Sainte-Blandine Service de Médecine Interne, METZ
-
Mario OJEDA-URIBE, PH · Centre Hospitalier Régional de MULHOUSE Hôpital Edouard Muller, Département d'Hématologie, Unité de thérapie cellulaire et greffes, MULHOUSE
-
Christophe RIDEL, PH · Hôpital Tenon, Service de Néphrologie et de Transplantation rénale, PARIS
-
François BRIVET, PH · Hôpital Antoine Béclère, Service de réanimation médicale, CLAMART
-
Sylvain LAVOUÉ, PH · CHU Pontchaillou, Service de maladies infectieuses et réanimation médicale, RENNES
-
Sébastien CANET, PH · Centre Hospitalier de Perpignan, Hôpital Saint-Jean, Service de Néphrologie, Hémodialyse, PERPIGNAN
-
François PROVOT, PH · Centre Hospitalier Régional Universitaire de Lille, Hôpital Calmette, Pôle de Néphrologie, LILLE
-
Claude GUYOT, PH · CHU de Nantes, Hôpital de jour et d'Hémodialyse pédiatrique
-
Xavier BELENFANT, PH · CHI André Grégoire de Montreuil, Service de Néphrologie, Diabète et Dialyse, MONTREUIL
-
Laurent PERARD, PH · Hôpital Edouard Herriot, Service de Médecine Interne, LYON
-
Edouard DEVAUD, PH · CHR de Pontoise Hôpital René Dubos, Service de Médecine Interne- Néphrologie- Dialyse, PONTOISE
-
Arnaud BUFFIN, PH · CH CHAMBERY, Service de Pédiatrie, CHAMBERY
-
Tarik KANOUNI, PH · CHU Montpellier Hôpital Lapeyronie, Service d'Hématologie et Oncologie médicale, MONTPELLIER
-
Nicolas GAMBIER, PH · Hôpital Avicenne, Service de Médecine Interne, BOBIGNY
-
Alain DEVIDAS, PH · CH Sud-Francilien- Hôpital Gilles de Corbeil, Service d'Hématologie Clinique, CORBEIL-ESSONNES
-
Laure FEDERICI, PH · CH Colmar- Hôpital Pasteur, Service de Médecine Interne, COLMAR
-
Michel FOULARD, PH · CHRU de Lille- Hôpital Jeanne de Flandre, Service de Néphrologie pédiatrique, LILLE
-
Serge BOLOGNA, PH · Hôpital Brabois Adulte, Service d'Hématologie, VANDOEUVRE-LÈS-NANCYS
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-11-30
- Primary Completion
- 2009-03-31
- Completion
- 2011-04-30
Countries
- France
Study Locations
More Related Trials
-
Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP
NCT04720261 ·Status: TERMINATED ·Phase: PHASE2
-
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT03922308 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
NCT01554514 ·Status: COMPLETED ·Phase: PHASE2
-
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
NCT05046717 ·Status: ACTIVE_NOT_RECRUITING
-
The ConNeCT Study: Neurological Complications of TTP
NCT04981028 ·Status: UNKNOWN
-
Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura
NCT06291025 ·Status: RECRUITING ·Phase: NA
-
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
NCT01520909 ·Status: COMPLETED ·Phase: PHASE3
-
NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults
NCT01172015 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00908037 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00828750 ·Status: COMPLETED ·Phase: PHASE3
-
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
NCT06137105 ·Status: NOT_YET_RECRUITING
-
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00454857 ·Status: COMPLETED
-
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
NCT01439321 ·Status: COMPLETED
-
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
NCT03393975 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00508820 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT04683003 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
NCT00251277 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
NCT00331357 ·Status: UNKNOWN
-
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
NCT01433978 ·Status: TERMINATED ·Phase: PHASE3
-
Research of Predictive Factors to Immune Thrombopenic Purpura
NCT01648556 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT01713738 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
NCT02273960 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
NCT01143038 ·Status: COMPLETED ·Phase: PHASE2
-
Aspirin for Prophylaxis of TTP
NCT05568147 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
NCT05046327 ·Status: WITHDRAWN ·Phase: PHASE3